Merck

Latest news

1. 26 Oct
   Moderna and Merck say personalized mRNA cancer vaccine cut melanoma death, recurrence 42%

   Moderna and Merck reported that a personalized mRNA cancer vaccine reduced death and recurrence in melanoma patients by 42%. The result comes from a clinical trial announced in October 2026.

   Research · 1 source

Articles

No articles about Merck yet.